STAT3-IN-36

STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016) . STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM.[1].

Product Specifications

CAS Number

[3055766-74-7]

UNSPSC

12352211

Target

STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/stat3-in-36.html

Smiles

O=S(C1=C(OC)C=C(OC)C2=C1OC(C3=CC=C(OC)C(S(=O)(NC4=CC=C(F)C=C4)=O)=C3)=CC2=O)(NC5=CC=C(F)C=C5)=O

Molecular Formula

C30H24F2N2O9S2

Molecular Weight

658.65

References & Citations

[1]Wu R, et al. Design, synthesis, and biological evaluation of novel 5,7,4'-trimethoxyflavone sulfonamide-based derivatives as highly potent inhibitors of LRPPRC/STAT3/CDK1. Bioorg Chem. 2024 Dec;153:107878.